Delayed nausea common for cancer patients receiving chemotherapy

July 10, 2003

Many more cancer patients who receive chemotherapy report a serious problem with nausea a day or two later than on the day of their treatment, according to a study published recently in Cancer, a journal of the American Cancer Society. The report shows that delayed nausea is a widespread problem for cancer patients who may feel fine when they walk out of the hospital or clinic and return home or to work, only to find themselves incapacitated two or three days later.

In a national study of 322 patients led by scientists at the James P. Wilmot Cancer Center at the University of Rochester Medical Center, 43 percent of patients reported being nauseous on the day of their chemotherapy treatment, while 73 percent reported nausea one or more days later. And those patients who felt ill in the days following treatment were twice as likely to report moderate or severe nausea than those who felt queasy on the first day.

"Surprisingly, 18 percent of patients didn't have any nausea at all until the third day. That's astonishing," says Jane T. Hickok, M.D., the lead author of the paper and research assistant professor of oncology and of community and preventive medicine. "And these were all patients who received medications to treat vomiting and nausea.

"Delayed nausea is a huge problem that is much more common than we've realized. People are anxious to get back to work, to get back to their lifestyle, and oftentimes they're surprised that they made it through the day of the treatment just fine, only to find themselves sick a day or two later."

The team studied patients who received one of three common chemotherapy drugs: doxorubicin, cisplatin, or carboplatin. On the day of treatment, all patients received standard therapy to prevent nausea, which included the steroid dexamethasone as well as a type of medication to prevent nausea known as a 5-hydroxytryptamine-3 receptor antagonist (5HT3), such as ondansetron.

These drugs first became available about a decade ago to reduce vomiting, or emesis. And since vomiting and nausea often go together, many patients and doctors assume that the drugs will prevent nausea too. In the study, while only 30 percent of patients experienced vomiting from their first treatment, 76 percent experienced nausea. In other words, even though patients are not stuck in the bathroom vomiting, they're often feeling nauseous and may not even get the relief that can come from finally throwing up.

"Twenty years ago, the most troublesome side effect of chemotherapy for patients was vomiting, but now, for many patients, nausea is much more troubling," says Hickok. "Nausea and vomiting are often treated as one and the same, but they are really very different processes. Many drugs have been very successful in controlling vomiting, but they don't seem so successful in controlling nausea, especially after the first day."

Since the study was completed, a new class of drugs that work differently than 5HT3 medications, known as neurokinin-1 or NK-1 receptor antagonists, has become available to treat nausea, and doctors are hopeful that these will prevent delayed nausea more effectively than the medications used in the study. And Hickok says that if doctors know that nausea is likely once the patient leaves the hospital, even prescribing traditional anti-nausea medicines like compazine may help.

Hickok led the study as part of a larger group run by Gary R. Morrow, Ph.D., who heads the Community Clinical Oncology Program, or CCOP, at the university's James P. Wilmot Cancer Center. The group, funded by the National Cancer Institute, specializes in improving the quality of life of people who have cancer by studying the symptoms of cancer and the side effects of treatment, such as fatigue, nausea, and shortness of breath.

CCOP studies are done in cooperation with community oncologists around the country - the arrangement brings the latest experimental treatments to patients in communities nationwide, and it helps researchers gather enough patients to ask and answer basic questions about cancer. In this study patients came from community practices in Seattle; Tacoma, WA; Columbus, OH; Honolulu; Marshfield, WI; St. Louis Park, MN; Hackensack, NJ; and Syracuse. Among the patients' diseases were leukemia and breast, lung, and uterine cancers.

In addition to Hickok and Morrow, authors of the report, which appeared in the June 1 issue of Cancer, were Joseph A. Roscoe, Ph.D., of the James P. Wilmot Cancer Center; David K. King, M.D., of the Greater Phoenix Community Clinical Oncology Program in Phoenix; James N. Atkins, M.D., of the Southeast Cancer Control Consortium in Winston-Salem, N.C.; and Tom R. Fitch, M.D., of a Mayo Clinic site in Scottsdale, AZ.
-end-


University of Rochester Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.